Literature DB >> 31281215

Prophylactic anti-coagulation after severe burn injury in critical care settings.

Megan Blake1, Ruth Roadley-Battin2, Tomasz Torlinski2.   

Abstract

BACKGROUND: Severely burnt patients are at an increased risk of thromboembolic complications, hence sufficient prophylactic anticoagulation is of paramount importance. Local guidelines at the Burns Centre in the Queen Elizabeth Hospital, Birmingham therefore advise increasing the standard dose of low molecular weight heparin in these patients. An audit was carried out to assess the current practice in burns patients to ensure adequate anticoagulation and adherence to guidelines.
MATERIALS AND METHODS: Retrospective data was collected on all burns patients in the Burns Centre over a two-year period. The main objectives were to assess:anticoagulation regimes prescribed to severe burns patientsmonitoring of Anti-Factor Xa levelsadjustment of dosing based on the resultsThe locally produced trust guidelines were used as the comparator.
RESULTS: All burns patients were prescribed anticoagulation, but often the dose was not increased as suggested in the guidelines. Although most of the severely burnt patients were prescribed adjusted higher doses of anti-coagulation, only 60% of these patients were monitored with Anti-Factor Xa assays. Of these assays, 66% showed sub-prophylactic levels. The majority of results led to the adjustment of the dose of anticoagulant. However, often dose changes were made late. DISCUSSION AND
CONCLUSIONS: The audit confirmed the need for increased doses of prophylactic anticoagulation in severe burns. The better adherence to the guidelines can be achieved by additional training and implementation of decision support via electronic prescribing system.

Entities:  

Keywords:  Anti-Factor Xa; anticoagulation; burns; heparin; intensive care; thermal trauma; thromboprophylaxis

Year:  2019        PMID: 31281215      PMCID: PMC6586379          DOI: 10.6001/actamedica.v26i1.3954

Source DB:  PubMed          Journal:  Acta Med Litu        ISSN: 1392-0138


  17 in total

1.  [Comparative study of errors in electronic versus manual prescription].

Authors:  O Delgado Sánchez; A Escrivá Torralva; M Vilanova Boltó; J Serrano López de las Hazas; M Crespí Monjo; M Pinteño Blanco; I Martínez López; P Tejada González; M Cervera Peris; F Fernández Cortés; F Puigventós Latorre; M A Barroso Navarro
Journal:  Farm Hosp       Date:  2005 Jul-Aug

2.  EMRs in the fourth stage: the future of electronic medical records based on the experience at Intermountain Health Care.

Authors:  Douglas Ivan Thompson; David C Classen; Peter J Haug
Journal:  J Healthc Inf Manag       Date:  2007

3.  Complications of the hypercoagulable status in burn injury.

Authors:  Juan P Barret; Peter G Dziewulski
Journal:  Burns       Date:  2006-08-01       Impact factor: 2.744

4.  Enoxaparin and antifactor Xa levels in acute burn patients.

Authors:  Hsin Lin; Iris Faraklas; Amalia Cochran; Jeffrey Saffle
Journal:  J Burn Care Res       Date:  2011 Jan-Feb       Impact factor: 1.845

5.  Evaluation of prophylactic anticoagulation, deep venous thrombosis, and heparin-induced thrombocytopenia in 21 burn centers in Germany, Austria, and Switzerland.

Authors:  Marc N Busche; Christian Herold; Robert Krämer; Karsten Knobloch; Peter M Vogt; Hans-Oliver Rennekampff
Journal:  Ann Plast Surg       Date:  2011-07       Impact factor: 1.539

6.  Enoxaparin dose adjustment is associated with low incidence of venous thromboembolic events in acute burn patients.

Authors:  Hsin Lin; Iris Faraklas; Jeffrey Saffle; Amalia Cochran
Journal:  J Trauma       Date:  2011-12

7.  Subcutaneous enoxaparin once or twice daily compared with intravenous unfractionated heparin for treatment of venous thromboembolic disease.

Authors:  G Merli; T E Spiro; C G Olsson; U Abildgaard; B L Davidson; A Eldor; D Elias; A Grigg; D Musset; G M Rodgers; A A Trowbridge; R D Yusen; K Zawilska
Journal:  Ann Intern Med       Date:  2001-02-06       Impact factor: 25.391

8.  Enoxaparin, effective dosage for intensive care patients: double-blinded, randomised clinical trial.

Authors:  Sian Robinson; Aleksander Zincuk; Thomas Strøm; Torben Bjerregaard Larsen; Bjarne Rasmussen; Palle Toft
Journal:  Crit Care       Date:  2010-03-18       Impact factor: 9.097

Review 9.  Influence of burns on pharmacokinetics and pharmacodynamics of drugs used in the care of burn patients.

Authors:  Benoit Blanchet; Vincent Jullien; Christophe Vinsonneau; Michel Tod
Journal:  Clin Pharmacokinet       Date:  2008       Impact factor: 6.447

Review 10.  Critical care of the burn patient: the first 48 hours.

Authors:  Barbara A Latenser
Journal:  Crit Care Med       Date:  2009-10       Impact factor: 7.598

View more
  2 in total

Review 1.  Burn management during the COVID-19 pandemic: recommendations and considerations.

Authors:  Amjad Soltany; Ali Ramez Hasan; Farah Mohanna
Journal:  Avicenna J Med       Date:  2020-10-13

2.  Heparin resistance in severe thermal injury: A prospective cohort study.

Authors:  Liam D Cato; Benjamin Bailiff; Joshua Price; Christos Ermogeneous; Jon Hazeldine; William Lester; Gillian Lowe; Christopher Wearn; Jonathan R B Bishop; Janet M Lord; Naiem Moiemen; Paul Harrison
Journal:  Burns Trauma       Date:  2021-10-20
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.